Form 4: Procept BioRobotics Director Larry Wood Reports Acquisition of Stock and Options

Director Larry Wood reports acquisition of 1,376 shares of common stock and options to purchase 2,526 shares of common stock in Procept BioRobotics Corp.

Summary

• On June 4, 2024, Larry Wood, a director of Procept BioRobotics Corp, acquired 1,376 shares of common stock.
• These shares were granted as restricted stock units (RSUs) that will vest on the earlier of June 4, 2025, or the date of the next annual meeting following the grant date, contingent upon continued service.
• Additionally, Mr. Wood acquired options to purchase 2,526 shares of common stock at an exercise price of $67.29 per share.
• These options also vest on the earlier of June 4, 2025, or the date of the next annual meeting following the grant date, contingent upon continued service.
• Following these transactions, Mr. Wood directly owns 4,430 shares of common stock and options to purchase 2,526 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating insider transactions, which doesn't inherently suggest positive or negative sentiment. The acquisition of shares and options could be seen as a positive sign, but it's a standard part of executive compensation.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.
• The vesting conditions tied to continued service align the director's interests with those of the shareholders.

Future Outlook

The vesting of the RSUs and stock options is contingent upon continued service, suggesting an expectation of ongoing involvement by the director.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in the beneficial ownership of securities by a director of Procept BioRobotics.

Comparison to Industry Standards

• Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry.
• Vesting schedules tied to continued service are standard practice to align management's interests with those of shareholders.
• The specific terms of the options and RSUs (exercise price, vesting period) would need to be compared to those of peer companies to assess their competitiveness.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment, as they indicate confidence from a company director.
• Employees may view the vesting conditions as a sign of stability and continued commitment from leadership.

Key Dates